B-cell malignancies, such as human Burkitt's lymphoma, often contain translocations that link c-myc or other proto-oncogenes to the immunoglobulin heavy chain locus (IgH, encoded by Igh) 1 . The nature of elements that activate oncogenes within such translocations has been a long-standing question. Translocations within Igh involve DNA double-strand breaks initiated either by the RAG1/2 endonuclease during variable, diversity and joining gene segment (V(D)J) recombination, or by activation-induced cytidine deaminase (AID, also known as AICDA) during class switch recombination (CSR) [2] [3] [4] . V(D)J recombination in progenitor B (pro-B) cells assembles Igh variable region exons upstream of m constant region (Cm) exons, which are the first of several sets of C H exons ('C H genes') within a C H locus that span several hundred kilobases (kb) 5, 6 . In mature B cells, CSR deletes Cm and replaces it with a downstream C H gene 6 . An intronic enhancer (iEm) between the variable region exons and Cm promotes V(D)J recombination in developing B cells 7 . Furthermore, the Igh 39 regulatory region (Igh39RR) lies downstream of the C H locus and modulates CSR by long-range transcriptional enhancement of C H genes [8] [9] [10] . Transgenic mice bearing iEm or Igh39RR sequences fused to c-myc are predisposed to B lymphomas, demonstrating that such elements can confer oncogenic c-myc expression [11] [12] [13] [14] [15] [16] . However, in many B-cell lymphomas, Igh-c-myc translocations delete iEm and place c-myc up to 200 kb upstream of the Igh39RR 1 . Here we address the oncogenic role of the Igh39RR by inactivating it in two distinct mouse models for B-cell lymphoma with Igh-c-myc translocations. We show that the Igh39RR is dispensable for pro-B-cell lymphomas with V(D)J recombination-initiated translocations, but is required for peripheral B-cell lymphomas with CSR-associated translocations. As the Igh39RR is not required for CSR-associated Igh breaks or Igh-c-myc translocations in peripheral B-cell lymphoma progenitors, we conclude that this regulatory region confers oncogenic activity by long-range and developmental stage-specific activation of translocated c-myc genes.
Individual C H genes are organized into germline transcription units which consist, from 59 to 39, of a non-coding 'I' exon, a switch (S) region and the C H exons 6 . CSR to a particular C H gene requires the introduction of AID-initiated DNA double-strand breaks (DSBs) into the donor S region upstream of Cm (Sm) and into a downstream acceptor S region 6 . The I exon is preceded by a germline promoter that is upregulated by particular activation treatments, with transcription targeting AID to specific S regions 17 . The Igh39RR contains multiple enhancer elements [18] [19] [20] and controls germline transcription of certain C H promoters over distances of 100 kb or more 8 . However, the Igh39RR is not required for V(D)J recombination, expression of rearranged Igh genes, or transcription through Sm or Sc1 (ref. 10) . To test the potential roles of the Igh39RR in B-cell lymphomagenesis, we bred an Igh39RR inactivating mutation, which deletes the key hs3b and hs4 enhancers 10 ( Supplementary Fig. 1 ), into non-homologous endjoining (NHEJ) and p53 tumour suppressor deficient backgrounds that predispose to either pro-B or peripheral B-cell lymphoma.
XRCC4 and DNA ligase 4 (Lig4) form a NHEJ ligation complex required for V(D)J recombination 21 . Mice with germline inactivation of either Lig4 or Xrcc4 and the p53 tumour suppressor develop pro-Bcell lymphomas with complex translocations ('complicons') involving Igh on chromosome 12 (chr12) and a region downstream of c-myc on chromosome 15 (chr15) 22 . These translocations arise from joining RAG1/2-induced DSBs in the Igh J H region to DSBs downstream of c-myc, leading to dicentric chr12;15 translocations and c-myc amplification by breakage-fusion-bridge cycles 22, 23 . Analysis of Lig4 and p53 double-deficient mice ('LP' mice) that contained Igh39RR inactivating mutations on either one or both Igh alleles (referred to as LPR 1/2 or LPR 2/2 , respectively) showed that both genotypes succumbed to pro-B-cell lymphomas with kinetics similar to those of LP mice 22 ( Fig. 1a and Supplementary Table 1 ). Likewise, all analysed LPR 1/2 and LPR 2/2 tumours had characteristic chr12 to chr15 translocations (T(12;15)) and 15;12 complicons (C(15;12)) containing amplified c-myc ( Fig. 1b , Supplementary Fig. 2 and Supplementary Table 1 ). Furthermore, Southern blotting with a probe that distinguishes Igh39RR-deleted from wild-type Igh alleles ( Fig. 1c , top) showed that Igh-c-myc translocations/amplifications involved the wild-type allele in some LPR 1/2 tumours and the Igh39RR-deleted allele in others (Fig. 1c, bottom) . Thus, the Igh39RR is dispensable for LP pro-B-cell lymphomas with Igh-c-myc complicons.
Specific inactivation of Xrcc4 by a loxP/Cre approach in peripheral B cells of p53-deficient mice (referred to as 'CXP' mice) leads to surface immunoglobulin-negative peripheral B-cell lymphomas 24, 25 . CXP B-cell lymphomas arise from progenitors that delete or aberrantly rearrange their Igk and Igl light-chain loci and routinely contain a T(12;15) that fuses Igh S regions to sequences just upstream of c-myc, leading to high level c-myc expression from a translocated single copy c-myc gene 25, 26 . Such T(12;15)s lack iEm, as they occur downstream of this element 24 . To test potential roles of the Igh39RR in CXP tumorigenesis, we followed tumour development in cohorts of CXPR 1/2 and CXPR 2/2 mice. CXPR 1/2 mice succumbed to the same tumour spectrum as CXP mice 25 , with 40% developing surface immunoglobulin-negative B-cell lymphomas that appeared identical to CXP B-cell lymphomas ( Fig. 2a and Supplementary Table 2 ). The remaining CXPR 1/2 mice succumbed to thymic lymphomas or other tumours associated with germline p53 deficiency. In contrast, none of 17 analysed CXPR 2/2 mice developed B-cell lymphoma; instead, most died from thymic lymphoma ( Fig. 2a and Supplementary Table 2 ). Thus, homozygous Igh39RR inactivation abrogates CXP B-cell lymphomas.
All analysed CXPR 1/2 B-cell tumours had a clonal T(12;15), on the basis of spectral karyotyping ( Fig. 3c and Supplementary Fig. 3 ). As in CXP B-cell lymphomas 25 , most T(12;15) from CXPR 1/2 B-cell lymphomas split c-myc, as evidenced by Southern blotting with 59 and 39 c-myc locus probes (Fig. 2b, top) . However, two tumours (393 and 959) had c-myc amplification without detectable c-myc rearrangements ( Fig. 2b) , and tumour 796, while harbouring a clonal T(12;15) that split c-myc, also contained metaphases with a translocation that fused this T(12;15) to chromosome 16, resulting in low level Igh/c-myc amplification ( Supplementary Fig. 3 and data not shown). Northern blotting showed increased c-myc expression in all CXPR 1/2 B-cell tumours, with tumours 393, 796 and 959 showing the highest levels ( Supplementary Fig. 4 ), suggesting that amplification may sometimes be selected secondary to ectopic activation to achieve maximal expression, which may be relevant to certain human lymphomas that acquire c-myc amplification during tumour progression 12 .
To determine which Igh allele was involved in CXPR 1/2 lymphoma T(12;15)s, we analysed tumour metaphases by fluorescence in situ hybridization (FISH) with a probe specific for the deleted portion of the Igh39RR (39RR wild-type probe, green) and a chr15 paint (red). In this assay, the translocated portion of chr15 (red paint) co-localizes with a green signal if the wild-type Igh allele is translocated, but not if the Igh39RR-deleted allele is translocated ( Fig. 3a, left) . Sequential re-probing of these metaphases with a green chr12 paint (2nd FISH, green) plus a 39 Igh BAC probe (2nd FISH, red) ( Fig. 3a , right) showed that all CXPR 1/2 tumour Igh-c-myc translocations involved the wild-type Igh allele (Fig. 3b, c Whole metaphases are presented in Supplementary Fig. 2 . c, Southern blot analysis of LPR 1/2 (left) and LPR 2/2 (right) tumour DNA with a probe downstream of hs4, which distinguishes the wild-type (WT) and 39RRdeleted (del) Igh alleles. A schematic of the wild-type and del Igh locus, with the position of the probe, is on the top. Numbers refer to individual mice in the cohort (see Supplementary Table 1 ). C, control, total spleen DNA from wild-type mouse; RI, EcoRI. Supplementary Table 2 ). gl, germ line; K, kidney, used as control; Tu, tumour. A schematic of the c-myc locus, indicating the 59 and 39 probes used to detect c-myc rearrangements is on the top. Numbers refer to individual mice in the cohort. Sequential hybridization with the set of probes indicated on the left was performed. Only chromosomes involved in translocations are shown, along with a graphic representation. The whole metaphases are presented in Supplementary Fig. 5 . c, Right: quantification of Igh locus breaks in B cells activated for 4 days with anti-CD40 and IL4 or for 5 days with LPS and anti-IgD-dextran, from control, CXPR 1/2 and CXPR 2/2 mice. At least three mice per each genotype and at least 60 metaphases per mouse were analysed; data are presented as mean and s.d. b, Southern blot analysis of CXPR 1/2 tumour DNA with a Cm probe that detects Sm rearrangements. A schematic of the Igh locus, indicating the probe position, is on the top. The position of germline bands in C57/B6 and 129/Sv backgrounds is indicated on the left; the 39RR-deleted allele is from 129/Sv background. Numbers refer to individual mice in the cohort. Note that in some cases kidneys contained infiltration of tumour cells, as judged by tumour-specific rearranged J H and c-myc bands (Fig. 2b) . c, Frequency of Igh-cmyc translocations was measured by PCR assays using Sm and c-myc primers. DNA samples were isolated from day 4 splenic B cells from wild-type, CX, CXPR 1/2 and CXPR 2/2 mice, activated with anti-CD40 and IL4. NATURE | Vol 462 | 10 December 2009 potential mechanisms, we asked whether the Igh39RR-deleted allele is a substrate for AID-induced DSBs. As one measure, we activated CXPR 1/2 and CXPR 2/2 B cells for 4 days with anti-CD40 and IL4 and found that both genotypes switched to IgG1, as expected by the fact that the 39IghRR is not required for CSR to this IgH isotype 8, 10 ( Supplementary Fig. 6a ). We also analysed metaphases from anti-CD40-and IL4-stimulated CXPR 1/2 and CXPR 2/2 B cells using two-colour FISH 27 and found that the increased level of Igh breaks in the absence of XRCC4 (ref. 24 ) was not markedly affected by the Igh39RR mutation (Fig. 4a ). CSR to IgG3 is severely impaired in mice homozygous for Igh39RR inactivating mutations due to inhibition of Ic3 transcription 8, 10 . However, lipopolysaccharide (LPS) and anti-IgD-dextran stimulation to induce IgG3 CSR led to similarly increased levels of Igh breaks in CXPR 1/2 and CXPR 2/2 B cells ( Supplementary Fig. 6b and Fig. 4a ), probably reflecting unimpeded AID activity on Sm, which is transcribed independently of the Igh39RR 10 . Southern blotting further showed that most CXPR 1/2 B-cell tumours had Sm rearrangements or deletions on both alleles, again indicative of substantial AID activity on Igh39RR-deleted alleles (Fig. 4b ). We conclude that the introduction of AID-induced Igh lesions is not markedly impaired by the Igh39RR deletion.
Although AID-induced Igh breaks occur at high frequency on Igh39RR-deleted alleles, Igh-c-myc translocations still might be inhibited, for example by a different distribution of Igh DSBs or by effects on proximity of the two loci 26 . Therefore, we used a PCR assay 28 to directly evaluate the potential effects of the Igh39RR deletion on Igh-cmyc translocation frequency, and found that Igh-c-myc translocations, indeed, occurred at similar frequencies in CXPR 1/2 and CXPR 2/2 B cells stimulated with anti-CD40 and IL4 (Fig. 4c ). Moreover, one CXPR 1/2 B-cell tumour had a T(12;11) involving the Igh39RR-deleted allele in addition to its T(12;15), again indicating the Igh39RR-deleted allele is a translocation target ( Fig. 3c and Supplementary Fig. 3 ). We conclude that the Igh39RR is dispensable for generation of Igh-c-myc translocations in XRCC4-deficient B cells.
The Igh locus has long been speculated to have cis-acting elements that activate c-myc or other oncogenes in the context of translocations. We now demonstrate that the Igh39RR is required for oncogenicity of Igh-c-myc translocations that ectopically activate c-myc in mouse CXP B-cell lymphomas. As a substantial proportion of CXPR 1/2 ( Supplementary Fig. 7 ) and CXP lymphomas 25 have translocations that fuse c-myc to Sm, oncogenic Igh39RR activity extends at least 200 kb upstream. Thus, our findings define a major oncogenic role for the Igh39RR in activating c-myc subsequent to Igh-c-myc translocations; although we do not rule out an additional role in promoting translocations by enhancing AID-mediated lesions in certain S regions regulated by this element. Although high-copy iEm transgenes predispose to pro-B-cell lymphoma in mice 12 , the role of iEm in Igh-oncogene translocations remains to be determined. In this context, knock-in of c-myc into the Igh J H region led to peripheral B-cell lymphomas, as opposed to pro-B-cell lymphomas 12 , suggesting that iEm alone may not always be sufficient to activate c-myc in the endogenous setting. In this regard, our finding that the Igh39RR is dispensable for LP pro-B-cell lymphomas may explain why c-myc is amplified in these tumours and ectopically activated in peripheral CXP B-cell tumours. Specifically, the Igh39RR is not active in pro-B cells 9 and would not activate Igh translocations upstream of a singlecopy c-myc, favouring selection for translocations downstream of c-myc that promote gene amplification. Given the similar organization of mouse and human Igh 9 , our findings suggest that the Igh39RR also supports activated oncogene expression in human B-cell tumours with Igh S region translocations that eliminate iEm (for example, sporadic Burkitt's lymphoma 29 ) and, potentially, even in some with Igh J H region translocations that leave iEm intact (for example, endemic Burkitt's lymphoma 29 ). In this regard, targeted inhibition of the B-cell-specific Igh39RR could theoretically provide a therapeutic strategy for such human B lymphomas.
METHODS SUMMARY
Mouse strains. Igh39RR-deleted mice were generated previously 10 and crossed into Lig4 1/2 p53 1/2 (ref. 30) or CD21-Cre, Xrcc4 c/c p53 1/2 (ref. 25 ) mice to obtain triple or quadruple heterozygous animals, which were appropriately crossed to obtain the experimental cohorts. Mice were analysed as outlined in the text at 8-30 weeks of age. The Institutional Animal Care and Use Committee of Children's Hospital (Boston, Massachusetts) approved all animal work. Splenic B-cell purification, activation in culture and CSR assays. CD43 2 B cells were isolated and cultured as previously described 27 . Cells were processed at day 4 of stimulation with anti-CD40 and IL4, or at day 5 of stimulation with LPS and anti-IgD-dextran for DNA isolation, metaphase preparation and flow cytometry analysis (see Methods). Two-colour FISH. Metaphase spreads were prepared and FISH experiments performed according to standard protocols 27 . FISH probes are detailed in Methods. Whole chromosome paints specific for mouse chromosome 12 and 15 were used according to the manufacturer's instructions (Applied Spectral Imaging). PCR assay to detect Igh-c-myc translocations. Igh-c-myc translocation junctions were amplified by PCR from genomic DNA prepared from splenic B cells activated for 4 days with anti-CD40 and IL4, using primers and conditions previously described 28 (see Methods) . DNA corresponding to 50,000 or 100,000 cells was analysed in separate reactions. PCR products were run on agarose gel, blotted and hybridized with an internal oligonucleotide probe in the c-myc locus.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
